| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/23/2009 | EP2102180A1 Substituted aminofuranones and their use |
| 09/23/2009 | EP2102177A1 Benzoxazoles useful in the treatment of inflammation |
| 09/23/2009 | EP2102176A2 Macrocyclic factor viia inhibitors useful as anticoagulants |
| 09/23/2009 | EP2102175A1 Triazole derivative as an hsp 90 inhibitor |
| 09/23/2009 | EP2102173A1 Pyrimidyl derivatives as protein kinase inhibitors |
| 09/23/2009 | EP2102171A1 New pyridazine derivatives with mch antagonistic activity and medicaments comprising these compounds |
| 09/23/2009 | EP2102170A2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 09/23/2009 | EP2102169A1 Indazolyl ester and amide derivatives for the treatment of glucocorticoid receptor mediated disorders |
| 09/23/2009 | EP2102168A1 Acylaminopyrazoles for treating cardiovascular diseases |
| 09/23/2009 | EP2102165A2 N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's |
| 09/23/2009 | EP2102164A1 Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives |
| 09/23/2009 | EP2102162A1 Phenylic derivatives and use thereof as drugs |
| 09/23/2009 | EP2102161A2 Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-methyl-2-oxopyridin-1(2h)-yl)-n,4-dimethylbenzamide |
| 09/23/2009 | EP2102158A1 Prodrugs of diphenyl ox- indol- 2 -one compounds for the treatment of cancers |
| 09/23/2009 | EP2102157A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives |
| 09/23/2009 | EP2102155A1 Aryl compounds as ppar ligands and their use |
| 09/23/2009 | EP2102154A1 Water-soluble prodrugs of chloramphenicol, thiamphenicol, and analogs thereof |
| 09/23/2009 | EP2102153A1 Ampa receptor potentiators |
| 09/23/2009 | EP2102139A2 Omega-3 lipid compounds |
| 09/23/2009 | EP2101991A1 Laminates of acid polysaccharide films |
| 09/23/2009 | EP2101877A2 Neutralization of cd95 activity blocks invasion of glioblastoma cells in vivo |
| 09/23/2009 | EP2101820A2 Combination of a retinoid and a platinum anticancer agent |
| 09/23/2009 | EP2101819A2 Methods, compositions, and kits for treating pain and pruritis |
| 09/23/2009 | EP2101806A2 Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor |
| 09/23/2009 | EP2101805A2 Specific therapy and medicament using integrin ligands for treating cancer |
| 09/23/2009 | EP2101799A2 Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals |
| 09/23/2009 | EP2101793A2 Composite material for tissue repair |
| 09/23/2009 | EP2101792A2 Use of carrageenan for treating rhinovirus infections |
| 09/23/2009 | EP2101791A2 Anticonnexin polynucleotides as impaired wound healing compositions |
| 09/23/2009 | EP2101790A1 Combination comprising cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agent |
| 09/23/2009 | EP2101788A2 D-ribose for treating suboptimal pulmonary function |
| 09/23/2009 | EP2101787A1 Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin |
| 09/23/2009 | EP2101786A2 Medicaments and methods for promoting wound contraction |
| 09/23/2009 | EP2101783A2 Method of preventing or treating myocardial ischemia |
| 09/23/2009 | EP2101782A2 Use of mtki 1 for treating or preventing bone cancer |
| 09/23/2009 | EP2101781A2 Method for treating or preventing symptoms of hormonal variations |
| 09/23/2009 | EP2101780A2 Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
| 09/23/2009 | EP2101779A1 Medical implants with a combination of compounds |
| 09/23/2009 | EP2101778A2 Agent for treating vascular leaks |
| 09/23/2009 | EP2101777A1 Composition for treating a pulmonary hypertension |
| 09/23/2009 | EP2101776A2 Treatment of anxiety with eszopiclone |
| 09/23/2009 | EP2101775A1 Reduction of cardiovascular symptoms |
| 09/23/2009 | EP2101774A2 7,8-saturated-4,5-epoxy-morphinanium analogs |
| 09/23/2009 | EP2101773A2 (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs |
| 09/23/2009 | EP2101772A1 Intermediate duration neuromuscular blocking agents and antagonists thereof |
| 09/23/2009 | EP2101771A2 Stable lercanidipine formulation |
| 09/23/2009 | EP2101770A2 Medicinal delivery system and related methods |
| 09/23/2009 | EP2101769A2 Methods for the treatment of alcohol abuse, addiction and dependency |
| 09/23/2009 | EP2101768A2 Use of neuroprotective compounds for obtaining drugs for treating neurodegenerative diseases |
| 09/23/2009 | EP2101767A2 An article comprising prasugrel |
| 09/23/2009 | EP2101766A1 Compositions and methods of using (r)-pramipexole |
| 09/23/2009 | EP2101765A1 Use of epothilones in the treatment of osteoporosis and related diseases |
| 09/23/2009 | EP2101764A2 Desferrithiocin analogue actinide decorporation agents |
| 09/23/2009 | EP2101763A2 Pharmaceutical compositions and their methods of use |
| 09/23/2009 | EP2101762A1 Novel 2 -imidazoles as ligands for trace amine associated receptors (taar) |
| 09/23/2009 | EP2101761A1 Methods for preserving renal function using xanthine oxidoreductase inhibitors |
| 09/23/2009 | EP2101760A2 Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor |
| 09/23/2009 | EP2101759A1 Methods of using mek inhibitors |
| 09/23/2009 | EP2101758A2 Steroid sulphatase inhibitors for treating hormone dependent cancer |
| 09/23/2009 | EP2101757A1 Compound for treatment or prevention of prostate-related diseases and pharmaceutical composition of colon delivery system containing the same |
| 09/23/2009 | EP2101756A2 Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound |
| 09/23/2009 | EP2101755A2 Polyalkyloxydibenz (c,e) oxepine derivatives as medicaments |
| 09/23/2009 | EP2101754A1 Use of entacapone in cosmetic, dermatological and pharmaceutical compositions |
| 09/23/2009 | EP2101753A2 Use of cytohesin inhibitors for chemically inducing longevity |
| 09/23/2009 | EP2101752A1 Use of prodrugs of gaba analogs for treating diseases |
| 09/23/2009 | EP2101751A1 Benzamide derivatives as ep4 receptor agonists |
| 09/23/2009 | EP2101750A2 Water-soluble phenicol prodrugs in a lipophilic vehicle system |
| 09/23/2009 | EP2101749A1 Pharmaceutical composition comprising shikonin derivatives from lithospermum erythrorhizon for treating or preventing diabetes mellitus and the use thereof |
| 09/23/2009 | EP2101748A2 Uses of incensole, incensole acetate and derivatives thereof |
| 09/23/2009 | EP2101746A1 V3 antagonists for the treatment or prevention of chronic pain |
| 09/23/2009 | EP2101744A2 Oral transmucosal nicotine dosage form |
| 09/23/2009 | EP2101741A2 Solid dispersion comprising a poorly water soluble drug |
| 09/23/2009 | EP2101737A1 Revaprazan-containing solid dispersion and process for the preparation thereof |
| 09/23/2009 | EP2101736A2 Homogeneous paste and gel formulations |
| 09/23/2009 | EP2101735A2 Nanoparticulate formulations and methods for the making and use thereof |
| 09/23/2009 | EP2101733A2 Powder formulation for valganciclovir |
| 09/23/2009 | EP2101732A2 Liposomal gel phthalocyanine preparation for photodynamic therapy of tumors and its manufacturing |
| 09/23/2009 | EP2101731A2 Endoxifen methods and compositions |
| 09/23/2009 | EP2101730A2 Galenic form for the transmucosal delivery of paracetamol |
| 09/23/2009 | EP2101727A2 Compounds, compostions, kits and methods of use to orally and topically treat acne and other skin conditions by adminstering a 19-nor containing vitamin d analog with or without a reyinoid |
| 09/23/2009 | EP2101726A2 New vaseline-free ointment compositions comprising a vitamin d derivative and possibly an anti-inflammatory steroid |
| 09/23/2009 | EP2101725A1 Use of l-carnitine or of alkanoyl l-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye drops |
| 09/23/2009 | EP2101722A1 Use of agglomerated hydroxyethylcellulose in pharmaceutical, personal care and household care applications |
| 09/23/2009 | EP2101720A1 Mild composition for skin disinfection |
| 09/23/2009 | EP2101580A2 Methods of use for cyclopamine analogs |
| 09/23/2009 | EP2101579A1 Means for improving cognitive functions and memory based on hydrogenated pyrido (4,3-b) indoles (variants), pharmacological means based thereon and method for the use thereof |
| 09/23/2009 | EP2101578A1 Means for the treatment of acute and chronic disorders of cerebral circulation, including insult, based on hydrogenated pyrido (4, 3-b) indoles (variants), pharmacological means based thereon and method for the use thereof |
| 09/23/2009 | EP2101575A2 Ace2 activator compounds and methods of use thereof |
| 09/23/2009 | EP2101574A2 Compounds and formulations suitable for radical scavenging |
| 09/23/2009 | EP2101571A1 Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
| 09/23/2009 | EP2101569A1 Crystalline solid rasagiline base |
| 09/23/2009 | EP1819713B1 Isoxazoline-indole derivatives with an improved antipsychotic and anxiolytic a ivity |
| 09/23/2009 | EP1814538B1 Method of delivering nasal spray |
| 09/23/2009 | EP1799204B1 Composition containing omega-3 fatty acids and omega-6 fatty acids |
| 09/23/2009 | EP1768748B1 Compositions comprising strontium and vitamin d and uses thereof |
| 09/23/2009 | EP1768649B1 Pharmaceutical composition of piperazine derivatives |
| 09/23/2009 | EP1709003B1 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole |
| 09/23/2009 | EP1699797B1 Pyrrolotriazine compounds as kinase inhibitors |
| 09/23/2009 | EP1682548B1 Pyridopyrimidinones for the treatment of cancer diseases |
| 09/23/2009 | EP1651213B1 Use of angiotensin ii receptor antagonists, especially telmisartan, in order to increase insulin sensitivity |